BMY is trading 4% up at $57.63 despite a lack of fresh company-specific headlines or catalysts.
- The move appears stock-specific as broader market indices are trading slightly lower today.
- There are no new earnings reports, FDA decisions, or major analyst calls directly tied to the price action.
- The advance may be a continuation of the stock's recent 30-day strength, breaking out of its recent mid-$50 range.